Obsidian Therapeutics, Inc.'s next confirmed earnings release is scheduled for April 1, 2027.
| Earnings Date | 4/1/2027 |
As of March 31, 2026, Obsidian Therapeutics, Inc. has 61.60M shares outstanding.
| Shares Outstanding | 61.60M |
As of March 31, 2026, Obsidian Therapeutics, Inc. maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.21 |
| Quick Ratio | 3.86 |
| Debt / Equity | -1.30 |
These figures cover the twelve months ended March 31, 2026. The company generates approximately - - in revenue per employee across its workforce of 3.00, a quick read on workforce productivity versus industry peers.
| Employee Count | 3.00 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 14.19 |
These figures cover the twelve months ended March 31, 2026.
| Pretax Income | -19.63M |
As of March 31, 2026, Obsidian Therapeutics, Inc. holds 58.76M in cash and equivalents against 3.60M in total debt, resulting in a net debt position of -26.44M. Total book value stands at -276.20M, with working capital of 48.81M providing operational flexibility.
| Cash & Cash Equivalents | 58.76M |
| Total Debt | 3.60M |
| Net Debt | -26.44M |
| Equity (Book Value) | -276.20M |
| Book Value Per Share | -4.48 |
| Working Capital | 48.81M |
These figures cover the twelve months ended March 31, 2026. After subtracting - - in capital expenditures, free cash flow totaled -22.01M - equivalent to -0.36 per share.
| Free Cash Flow | -22.01M |
| FCF Per Share | -0.36 |
Obsidian Therapeutics, Inc.'s most recent stock split took place on July 13, 2026 with a 200:1 split ratio.
| Last Split Date | 7/13/2026 |
| Split Ratio | 200:1 |